Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Daniel Camprubí, Alex Almuedo-Riera, Helena Martí-Soler, Àlex Soriano, Juan Carlos Hurtado, Carme Subirà, Berta Grau-Pujol, Alejandro Krolewiecki, José Muñóz
Abstract
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
Topics & Concepts
IvermectinMedicineCoronavirus disease 2019 (COVID-19)Clinical trialRandomized controlled trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicineVirologyVeterinary medicineDiseaseOutbreakInfectious disease (medical specialty)Parasitic Diseases Research and TreatmentParasites and Host InteractionsDermatological diseases and infestations